Document Detail


Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
MedLine Citation:
PMID:  11805499     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To evaluate topical interferon alpha-2b (IFNalpha2b) as a lone therapy in the treatment of primary conjunctival and corneal intraepithelial neoplasia (CIN). METHODS: Noncomparative, prospective, interventional case series. Seven patients from three institutions, treated between February and October 1999, with presumed primary CIN lesions (clinically diagnosed by corneal specialists) were given topical IFNalpha2b drops (1 million units/mL) four to six times daily. Follow-up was performed biweekly until there was complete clinical resolution of the presumed CIN lesions. Patients were to continue topical IFNalpha2b drops for 1 month after clinical resolution. Patient charts and clinical photographs were reviewed, and data were analyzed. RESULTS: All seven eyes had complete resolution of the presumed CIN lesions after an average of 77.0 +/- 59.2 days (range, 28-188 days). Average posttreatment follow up was 12.4 +/- 2.5 months (range, 9-16 months). No patients were lost to follow-up. No recurrences have yet been seen. Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in four (57.1%) eyes. In all cases, there was total resolution of conjunctival hyperemia and follicular changes within 1 month after cessation of the medication, without additional treatment. CONCLUSIONS: Topical IFNalpha2b alone may be an effective treatment of primary CIN. It appears to be a safe alternative to radiation, intralesional IFNalpha2b injection, and surgical excision with cryotherapy. Larger population studies with longer follow-up are recommended to better assess the risk of recurrence and other possible adverse effects.
Authors:
Barry A Schechter; Amilia Schrier; Robert S Nagler; Edward F Smith; Gabriel E Velasquez
Related Documents :
16863959 - Excimer laser-assisted anterior lamellar keratoplasty for keratoconus, corneal problems...
6722069 - Long-term follow-up of intraocular lens implants: the first 127 compared with the lates...
14509459 - Anterior stromal puncture for bullous keratopathy.
19842609 - Prospective randomized trial of limbal relaxing incisions combined with microincision c...
12096959 - Time course of changes in corneal forward shift after excimer laser photorefractive ker...
9797659 - Do patients with age related maculopathy and cataract benefit from cataract surgery?
18766359 - Tracheostomy in young patients: indications and long-term outcome.
16505969 - Management of haemorrhagic type moyamoya disease with intraventricular haemorrhage duri...
23538719 - Methotrexate versus azathioprine in second line therapy of sarcoidosis.
Publication Detail:
Type:  Case Reports; Clinical Trial; Journal Article    
Journal Detail:
Title:  Cornea     Volume:  21     ISSN:  0277-3740     ISO Abbreviation:  Cornea     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-01-28     Completed Date:  2002-05-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  6-11     Citation Subset:  IM    
Affiliation:
Rand Eye Institute, Pompano Beach, Florida 33064, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Aged
Aged, 80 and over
Antineoplastic Agents / administration & dosage,  therapeutic use*
Carcinoma in Situ / drug therapy*
Conjunctival Neoplasms / drug therapy*
Corneal Diseases / drug therapy*
Eye Neoplasms / drug therapy*
Female
Humans
Interferon Alfa-2b / administration & dosage,  therapeutic use*
Male
Middle Aged
Ophthalmic Solutions
Remission Induction
Safety
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Ophthalmic Solutions; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacologic treatments for dry eye: a worthwhile investment?
Next Document:  The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal...